MTND1P22

Across TCGA pan-cancer cohorts, MTND1P22 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MTND1P22’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MTND1P22 RNA is repressed in tumor relative to normal tissue. In most cancer types MTND1P22 is over-expressed in tumor, although a few such as LIHC and KIRC show the opposite, repressed pattern.

LIHC and KIRC are the cancer types where MTND1P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTND1P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−0.025	.012	3	view →
KIRC	All	IV	−0.016	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

MTND1P22–LIHC

Open the LIHC breakdown →